<DOC>
	<DOCNO>NCT01242670</DOCNO>
	<brief_summary>The purpose study verify safety adequacy immune response produce 2.5 µg , adjuvanted ( aluminium hydroxide ) dose Ross River Virus ( RRV ) vaccine demonstrate consistency manufacture 3 separate lot RRV vaccine .</brief_summary>
	<brief_title>Ross River Virus ( RRV ) Vaccine Study</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Subject 16 59 year age day screen ( Stratum A ) Subject 60 year age old day screening ( Stratum B ) Subject , applicable , subject 's parent ( ) /legal guardian ( ) ( /have ) understand study procedure , agree provision , give write informed consent prior study entry Subject provide write assent accord his/her age , applicable Subject generally healthy determine investigator 's clinical judgment base upon medical history physical examination Subject physically mentally capable participate study follow study procedure Subject agree keep daily record symptom duration study If female childbearing potential subject negative urine pregnancy test result within 24 hour schedule first vaccination agree employ adequate birth control measure duration study Subject Body Mass Index &gt; 35.0 Subject elevate blood pressure screen &gt; 159 mmHg systolic and/or &gt; 99 mmHg diastolic seat rest confirm 2 additional measurement take least 30 minute apart ( seat rest ) Subject inherit acquire immune deficiency Subject recent history significant neurological , cardiovascular , respiratory ( include asthma ) , hepatic , metabolic , rheumatic , autoimmune , hematological renal disorder Subject history arthritis ( include RRV disease , joint swelling , tenderness , warmth erythema ) one occasion , relate trauma ( include run ) episode nontrauma related arthritis within previous 6 month Subject disease currently undergoing form treatment undergoing form treatment within 30 day prior study entry could expect influence immune response . Such treatment include , limited , systemic high dose inhale ( &gt; 800 μg/day beclomethasone dipropionate equivalent ) , corticosteroid , radiation treatment immunosuppressive cytotoxic drug Subjects receive vaccination within 30 day prior study entry Subject receive blood transfusion immunoglobulin within 90 day prior study entry Subject donate blood plasma within 30 day prior study entry Subject history vaccine relate contraindicate event ( eg , anaphylaxis , allergy component test vaccine , know contraindication ) Subject dermatologic condition tattoo may interfere injection site reaction rating Subject participate another clinical study involve investigational drug , biological product device within 30 day prior enrollment study schedule participate another clinical study involve investigational drug , biological device course study Subject functional surgical asplenia Subject know suspect problem alcohol drug abuse Subject member team conduct study dependent relationship one study team member . Dependent relationship include close relative ( ie , child , partner/spouse , sibling , parent ) well employee investigator site personnel conduct study Subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>